|
|
|
|
|
Inactive Indication- |
Drug Highest PhasePhase 1 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
|
|
|
Inactive Indication- |
Drug Highest PhaseDiscovery |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target- |
Mechanism- |
Active Org.- |
|
Active Indication- |
|
Drug Highest PhasePending |
First Approval Ctry. / Loc.- |
First Approval Date- |
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of Escalating Single and Multiple Doses of FB1003 in the Healthy Subjects
The purpose of this study is to evaluate safety and tolerability of FB1003 when given subcutaneously to healthy participants. Blood tests will be done to examine blood exposure, concentration and half-life of FB1003 following administrations. For each participant, the study will last up to about 12 weeks for single ascending dose part, and 18 weeks for multiple ascending dose part, including screening.
中国成年健康受试者口服 FB-1071 的食物影响药代动力学研究
[Translation] Food-Effected Pharmacokinetic Study of Oral FB-1071 in Chinese Adult Healthy Subjects
评估食物对中国健康成人受试者口服 FB-1071 后暴露量参数的影响。
[Translation] To assess the effect of food on exposure parameters following oral administration of FB-1071 in healthy Chinese adult subjects.
评价 FB-1071 在中国成年健康受试者单次给药的安全性、耐受性、药代动力学的随机双盲安慰剂对照的 I 期临床研究
[Translation] A randomized double-blind placebo-controlled phase I clinical study evaluating the safety, tolerability, and pharmacokinetics of a single dose of FB-1071 in Chinese adult healthy subjects
观察FB-1071在中国成年健康受试者中单次给药后的安全性和耐受性。
[Translation] To observe the safety and tolerability of FB-1071 after a single dose in Chinese adult healthy subjects.
100 Clinical Results associated with 4B Technologies (Beijing) Co., Limited
0 Patents (Medical) associated with 4B Technologies (Beijing) Co., Limited
100 Deals associated with 4B Technologies (Beijing) Co., Limited
100 Translational Medicine associated with 4B Technologies (Beijing) Co., Limited